Benepali™ (etanercept) is indicated for the treatment of immune-mediated inflammatory diseases (rheumatological and dermatological diseases).
a Benepali™ is the etanercept market leader in the combined pharmaceutical markets in Europe where Benepali™ is launched and where we have data from IQVIA/MIDAS. Calculation based on single units (SU). Markets are: Austria, Belgium, Czech Rep, Denmark, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK.
Key safety information to help with Benepali™ (etanercept) use in clinical practice.